A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling

A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers

(2021) Mosaad I. Morsy et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens

(2021) Ibraam E. Mikhail et al.   MICROCHEMICAL JOURNAL

Role of favipiravir in the treatment of COVID-19

(2020) Shashank Joshi et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma

(2020) Safa M. Megahed et al.   SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

HPLC-UV method for quantification of favipiravir in pharmaceutical formulations

(2020) İbrahim Bulduk   ACTA CHROMATOGRAPHICA

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

(2017) Thi Huyen Tram Nguyen et al.   PLoS Neglected Tropical Diseases

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever

(2015) Brian B. Gowen et al.   ANTIVIRAL RESEARCH

Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells

(2009) D. F. Smee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY